LIVE

IBRX

ImmunityBio, Inc.

IBRX

NASDAQ·Healthcare·Biotechnology·Mkt cap $9.6B

$9.44

▲ +2.61%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$1.95 - $12.43

P/E

-11.06

Fwd P/E

-33.48

Beta

0.10

Div Yield

0.00%

Avg Vol

14.4M

Shares Out

1.0B

Mkt Cap

$9.6B

Price action

Price chart

Up 248.5% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Multi-platform technology approach reducing single-asset risk
  • Strategic partnerships with NCI and leading biotech collaborators
  • Diverse clinical pipeline spanning solid and liquid tumors
  • Proprietary natural killer and T cell engineering capabilities
▼

Bear Case

2 risks

  • Low volatility (beta 0.1).
  • Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.

Growth

Strong growth ahead

Phase II/III clinical trial progression for multiple cancer indications

Value

Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.

Momentum

Hot

+26.0% over 3m

Quality

Excellent

High-growth business (352% revenue growth, 94% gross margin). Pre-profit but investing in growth.

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 11, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of -$0.62 vs -$0.08 consensus (-675.0% surprise). Revenue of $44.2M vs $43.1M expected (+2.6%).

EPS miss
Rev beat +2.6%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-675.0%

Next: May 11, 2026

Revenue trend · last 8Q

—

—

—

—

+2424%

+425%

+407%

+168%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$1.0M

$6.1M

$7.6M

$16.5M

$26.4M

$32.1M

$38.3M

$44.2M

Margins · last 8Q

Gross

—

Operating

—

Profit

-1431.4%

View full earnings history →

Wall Street consensus

4 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

4

100%

Hold

0%

Sell

0%

Median Price Target

$12.00

▲ +27.1% vs $9.44

Low $12.00
Median $12.00
High $12.00

Latest: BTIG · May 21, 2026

1 analyst covering

View full analyst page →

vs Industry

How IBRX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.